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Original article
Pulse wave velocity (PWV), a measure of arterial stiffness, is 
an emerging screening tool for risk assessment in hyperten-
sion1 and for cardiovascular disease (CVD).2 Carotid-femoral 
PWV (cfPWV) represents central arterial stiffness and is 
considered the reference standard measure of aortic stiff-
ness.2 Additional measures of PWV include brachial-ankle 
PWV (baPWV) that represents both central and peripheral 
arterial stiffness, and femoral-ankle (faPWV) that represents 
peripheral arterial stiffness. The latter 2 measures are being 
evaluated for risk assessment, specifically baPWV, because of 
the ease of measurement technique compared with cfPWV.
Despite the interest in arterial stiffness, the repeatability 
of segment-specific PWV has not been fully examined, espe-
cially in a multicenter, population-based setting. Previous 
studies have shown acceptable repeatability of cfPWV 
using various devices, such as the Complior (Alam Medical, 
Vincennes, France) and SphygmoCor (Atcor Medical, 
Sydney, Australia),3–5 but there is limited information for 
segment-specific measures of PWV.6 Moreover, the current 
literature primarily reports statistics that do not speak to 
repeatability, such as the correlation coefficient that indicates 
the strength of a linear relationship between 2 variables7,8 and 
the coefficient of variation that is a marker of precision.9,10
The aim of this study, therefore, was to characterize the 
repeatability of central, lower-extremity, and composite 
measures of PWV from an automated waveform analyzer 
(VP-1000 Plus) in a multicenter, population-based study of 
older adults. Accurate assessment of the reproducibility of 
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BACKGROUND
Arterial stiffness measures are emerging tools for risk assessment 
and stratification for hypertension and cardiovascular disease 
(CVD). Carotid-femoral pulse wave velocity (cfPWV) is an estab-
lished measure of central arterial stiffness. Other measures of PWV 
include femoral-ankle (faPWV), a measure of peripheral stiffness, 
and brachial-ankle PWV (baPWV), a composite measure of central 
and peripheral stiffness. Repeatability of central, peripheral, and 
composite PWV measures has not been adequately examined or 
compared.
METHODS
Participants (n = 79; mean age 75.7 years; USA) from a repeatability 
study nested within the Atherosclerosis Risk in Communities (ARIC) 
Study visit 5 (2011–2013) underwent 2 standardized visits, 4–8 
weeks apart. Trained technicians obtained 2 PWV measurements at 
each visit using the VP-1000 Plus system. We calculated the intra-
class correlation coefficient (ICC), SE of measurement, and minimal 
detectable change (MDC95; 95% confidence interval) and difference 
(MDD).
RESULTS
The ICCs and 95% confidence intervals (95% CIs) were 0.70 (0.59, 
0.81) for cfPWV, 0.84 (0.78, 0.90) for baPWV, and 0.69 (0.59, 0.79) for 
faPWV. The MDC95 between repeat measures within an individual was 
411.0 cm/s for cfPWV, 370.6 cm/s for baPWV, and 301.4 cm/s for faPWV. 
The MDD for 2 independent samples of 100 per group was 139.3 cm/s 
for cfPWV, 172.3 cm/s for baPWV, and 100.4 cm/s for faPWV.
CONCLUSIONS
Repeatability was acceptable for all PWV measures in a multicenter, 
population-based study of older adults and supports its use in epide-
miologic studies. Quantifying PWV measurement variation is critical for 
applications to risk assessment and stratification and eventual transla-
tion to clinical practice.
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PWV measures is critical to their analysis and interpreta-
tion, and for applications to risk assessment and stratifica-
tion, and translation to clinical practice.
METHODS
Study population
This analysis included members of the Atherosclerosis 
Risk in Communities (ARIC) Study that were invited to 
participate in a repeatability study in 2011–2013. The ARIC 
Study is a population-based, longitudinal study of 15,792 
participants aged 45–64  years enrolled between 1987 and 
1989 from the following 4 US communities: Forsyth County, 
North Carolina; the city of Jackson, Mississippi; suburbs of 
Minneapolis, Minnesota; and Washington County, Maryland. 
Details of the initial visit have been previously described.11
At the most recent ARIC clinic exam (visit 5), staff at each 
of 4 field centers asked the first eligible participant seen each 
month if he/she was willing to return 4–8 weeks later to 
repeat the study visit. The mean follow-up time was 40.3 days 
(SD 9.5 days; range 27.9 to 71.5 days). If the participant was 
not interested, the staff recruited the next eligible and will-
ing participant for the repeatability study. The repeatability 
study included 82 participants representing the 4 field cent-
ers (20 Forsyth County, NC; 23 Jackson, MS; 19 Minneapolis, 
MN; 20 Washington County, MD). Participants were asked to 
fast for 8 hours, refrain from tobacco, caffeinated beverages, 
and vigorous physical activity in the morning of the visit, and 
bring all prescription and nonprescription medications taken 
within 2 weeks of the visit. We excluded participants with evi-
dence of a major arrhythmia on a 12-lead electrocardiogram 
(n = 1; Minnesota code 8-3-1), aortic stenosis (n = 1), or body 
mass index ≥40 kg/m2 (n = 1) due to concerns about inter-
ference with PWV measurements. After exclusions, our ana-
lytic sample included 79 participants. Participants provided 
written informed consent, and the study was approved by the 
Institutional Review Boards at the field centers, coordinating 
center, and central labs and reading centers.
Pulse wave velocity
Trained technicians obtained 2 PWV measurements fol-
lowing the same standardized protocol at each exam 4–8 
weeks apart. Details of the PWV methodology for ARIC 
have been reported elsewhere.12 Briefly, technicians meas-
ured PWV using the automated waveform analyzer VP-1000 
Plus (Omron, Kyoto, Japan)13 after participants were supine 
for 5–10 minutes. Carotid and femoral arterial pressure wave-
forms were acquired by applanation tonometry sensors on 
the left common carotid artery and left common femoral 
artery. Bilateral brachial and posterior-tibial arterial pressure 
waveforms were detected by plethysmographic and an oscil-
lometric pressure sensor wrapped on both arms and ankles. 
The electrodes and sensors were not removed when repeating 
measurements within-visit.
PWV was calculated as distance divided by transit time. 
Distance for cfPWV was measured with a segmometer 
(Rosscraft, Surray, Canada) and calculated as the distance 
between the suprasternal notch to carotid minus the carotid 
to femoral distance. Distances for baPWV and faPWV were 
automatically calculated by the VP-1000 Plus using height-
based formulas, as previously described.14 The right baPWV 
and faPWV measurements were used for this analysis, but left 
and right PWV measurements are included in Supplementary 
Tables 1–4). Outliers, defined as PWV values 3 SDs above or 
below the mean, were excluded from the analyses.
Quality control procedures for the parent study (≥4,900 
PWV measurements) included central training and recer-
tification, quarterly equipment calibration, and ongoing 
quality control reviews by one of the authors (H.T.) on a 
random sample of 40 records per month stratified by center 
with feedback provided to technicians.12 Approximately 
78% of records were considered optimal quality, 17% were 
good quality, 3% were acceptable, and none were poor or 
unacceptable.
Statistical analysis
Within- and between-visit summary measures of PWV 
were estimated as means and SDs. We calculated the aver-
age and absolute difference between pairs of measurements 
within-visit and between-visit.
We used a nested random-effects analysis of variance 
model to estimate the between-participant (σ2p), between-
visit (σ2bv), and within-visit (σ2wv) variation. The model was as 
follows: Yijk = µ + Personi + Visit(Person)j(i) + Errork(ij), where 
Y is the PWV index, µ is the intercept, i is 1, 2, 3 to the 79th 
participant, j is visit 1 or visit 2, and k is the first or second 
measurement. Our assumptions were that the between-visit 
variation is the same for all participants and the within-visit 
variation is the same for all visits and all participants.
To estimate the repeatability of PWV measures, the intra-
class correlation coefficient (ICC) was calculated by divid-
ing the between-participant variance by the total variance 
(
σ
σ
σ
σ σ σ
p p
p bv wv
2
2
2
2 2 2
total
=
± ±
). We also calculated the standard 
error of measurement (SEM) that represents the amount of 
measurement error, or repeatability, within an individual, 
SEM =  σ σbv wv
2 2± . Additionally, we estimated changes in 
PWV beyond measurement error measures based on the 
variance and sample size for 1- and 2-sample study designs. 
We calculated the minimal detectable change with 95% 
confidence (minimal detectable change, MDC95) between 
2 time points for an individual that reflects true change 
above measurement error ( SEM )MDC95 2 1 95= × √ × . . For a 
2-sample study design, we calculated the minimal detectable 
difference (MDD) between 2 measurements that reflects true 
change above measurement error between 2 independent 
samples, 
MDD =
2 2×
× ±( ) ( )
σ total
N
t tdf df( )∝ β , where df = 2 × 
n − 2.  We
 performed a sensitivity analysis adjusting vari-
ance estimates and the ICC for heart rate, to account for the 
strong association between PWV and heart rate. Analyses 
were performed using SAS, version 9.2 (SAS Institute, Cary, 
NC) and all statistical tests are 2-sided with nominal statisti-
cal significance level of P < 0.05.
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RESULTS
The mean age of the participants was 75.7 years and the 
mean body mass index was 29.6 kg/m2 (Table 1). There were 
46 (58.2%) females and 26 (32.9%) African Americans. The 
mean values for cfPWV, baPWV, and faPWV were fairly 
consistent within- and between-visits (Table 2). The average 
mean difference between-visit was higher than the average 
mean difference within-visit for all PWV measures except 
for cfPWV. The absolute mean difference between visit was 
higher than the absolute mean difference within-visit for all 
PWV measures.
Between-participant variation accounted for the 
majority of the total variation among all PWV measures 
(Table 3). The between-visit variation was higher than the 
within-visit variation for baPWV, but not for cfPWV and 
faPWV. The ICC (95% confidence interval) was 0.70 (0.59, 
0.81) for cfPWV, 0.84 (0.78, 0.90) for baPWV, and 0.69 
(0.59, 0.79) for faPWV (Table 4). The number of replicates 
to achieve an ICC of 0.90 was 6 for cfPWV and faPWV 
and 3 for baPWV, calculated with the Spearman-Brown 
formula.15
The MDC95 was 411 cm/s for cfPWV, 371 cm/s for baPWV, 
and 301 cm/s for faPWV (Table  4). The MDC95 between 
repeat measures within an individual was ≈1 SD for baPWV 
and ≈1.5 SDs for cfPWV and faPWV (Table 4). The MDD 
for 2 independent samples of 100 people per group was 
139 cm/s for cfPWV, 172 cm/s for baPWV, and 100 cm/s for 
faPWV (Figure 1; Supplementary Table 4), which is approxi-
mately 0.5 SD for cfPWV, baPWV, and faPWV. Since differ-
ences in heart rate could affect the repeatability of PWV, we 
adjusted for heart rate in a sensitivity analysis and obtained 
similar results.
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Table 1. Participant characteristics of the PWV repeatability study 
(N = 79)
Characteristic Mean ± SD or n (%)
Age, years 75.7 ± 4.6
Body mass index, kg/m2 29.6 ± 4.0
Female, n (%) 46 (58.2)
Non-Caucasian, n (%) 26 (32.9)
Current smoker, n (%) 1 (1.3)
Diabetes, n (%) 34 (43.6)
Hypertension, n (%) 58 (74.4)
Medication use, n (%)
 Beta-blocker, n (%) 28 (37.8)
 Alpha-blocker, n (%) 3 (4.1)
 Diuretic, n (%) 33 (44.6)
 Angiotensin-converting  
 enzyme inhibitor, n (%)
23 (31.1)
 Calcium channel blocker, n (%) 16 (21.6)
 Angiotensin receptor blocker, n (%) 18 (24.3)
Abbreviation: PWV, pulse wave velocity.
DISCUSSION
To our knowledge, this study is the first to report the short-
term repeatability of segment-specific PWV measures in a 
population-based cohort study. Our analysis showed that the 
repeatability of baPWV is excellent and that of cfPWV and 
faPWV is fair, according to the ICC interpretation recom-
mended by Fleiss.16 As expected, the majority of the vari-
ation was between-participant. Within-visit variation was 
smaller than the between-visit variation for baPWV, but was 
higher for faPWV and similar for cfPWV.
The between-visit variation estimated in our models rep-
resents the additional variation that is added when the PWV 
measurements are repeated 4–8 weeks apart, above that of 
the variation that occurs when the PWV measurements 
are repeated within minutes. For cfPWV, the within- and 
between-visit variation was similar. For baPWV, the within-
visit variation was lower than the between-visit variation, 
suggesting that more variation was added between-visits. 
For faPWV, the within-visit variation was higher than the 
between-visit variation suggesting that little variation was 
added when relating 2 faPWV measurements from different 
visits compared to relating faPWV from the same visit.
Repeatability has been reported primarily for cfPWV 
using the Complior and SphygmoCor devices, although 
most studies presented statistics that do not reflect repeat-
ability, focused on within- and between-observer repro-
ducibility, and were limited to measurements taken on the 
same day. There are, however, a few higher quality reports of 
cfPWV repeatability. For measurements taken on the same 
day at a single site, the ICC for pairs of cfPWV measurements 
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repeatability of baPWV is excellent and that of cfPWV and 
faPWV is fair, according to the ICC interpretation recom-
mended by Fleiss.16 As expected, the majority of the vari-
ation was between-participant. Within-visit variation was 
smaller than the between-visit variation for baPWV, but was 
higher for faPWV and similar for cfPWV.
The between-visit variation estimated in our models rep-
resents the additional variation that is added when the PWV 
measurements are repeated 4–8 weeks apart, above that of 
the variation that occurs when the PWV measurements 
are repeated within minutes. For cfPWV, the within- and 
between-visit variation was similar. For baPWV, the within-
visit variation was lower than the between-visit variation, 
suggesting that more variation was added between-visits. 
For faPWV, the within-visit variation was higher than the 
between-visit variation suggesting that little variation was 
added when relating 2 faPWV measurements from different 
visits compared to relating faPWV from the same visit.
Repeatability has been reported primarily for cfPWV 
using the Complior and SphygmoCor devices, although 
most studies presented statistics that do not reflect repeat-
ability, focused on within- and between-observer repro-
ducibility, and were limited to measurements taken on the 
same day. There are, however, a few higher quality reports of 
cfPWV repeatability. For measurements taken on the same 
day at a single site, the ICC for pairs of cfPWV measurements 
ranged from 0.94 to 0.98 taken 3 times with the same techni-
cian using the Complior.17 The mean difference between any 
3 pairs of measurements ranged from 3 to 10 cm/s, which 
is lower than the observed within-visit mean difference of 
−35 cm/s in cfPWV in the current study.
Similar to our results for cfPWV measured in repeat vis-
its, the repeatability of cfPWV was fair for the Complior 
(ICC = 0.62, SEM = 69 cm/s) and SphygmoCor (ICC = 0.56, 
SEM = 69 cm/s) among 20 healthy men and women (mean 
age 25)  who came for 3 visits on separate days with the 
same technician.5 The mean difference between the first 
2 measurements was 13 ± 115 cm/s for the Complior and 
11 ± 84 cm/s for the SphygmoCor. These estimates are com-
parable to the median intra-individual difference of 8 cm/s in 
cfPWV among 125 participants that had repeat PWV meas-
ures within 60 days using SphygmoCor in the Whitehall II 
Study.18 These between-visit differences and ICCs corre-
spond to the between-visit difference of 11 cm/s in cfPWV 
and ICC of 0.70 for cfPWV observed in the current study.
Unlike cfPWV, there are fewer repeatability studies of 
baPWV. The ICC for baPWV was 0.90 (0.87–0.94) in a ran-
dom sample of participants from a multicenter cohort study 
who had PWV measured twice in 2 visits within 90 days; the 
estimated sources of variation were 80.1% for between-sub-
ject, 8.1% for technician, 7.8% for between-visit, and 4.0% 
for measurement error using the VaSera VS-1500N (Fukuda 
Denshi, Tokyo, Japan).19 This is similar to the ICC of 0.84 
for baPWV in this study, and that 84% of the variation was 
due to between-subject and 13% was due to between-visit 
variation. The average between-visit difference in baPWV 
was −26.2 cm/s in our study, which is similar to a reported 
mean difference of 29 ± 202 cm/s in baPWV between meas-
urements taken 4 weeks apart in a study consisting of a select 
group of participants with essential hypertension using the 
Colin device (the same device as the Omron used in this 
study).20
Only one study has reported the repeatability for central, 
lower-extremity, and composite measures of PWV obtained 
simultaneously. Using the same device as the current study, 
Table 3. Components of measurement variation for PWV 
measures
Source of variation
cfPWV baPWV faPWV
SD % Total SD % Total SD % Total
Between-participant 227.8 70.2 308.4 84.2 162.8 69.2
Between-visit 96.2 12.5 122.4 13.2 58.5 8.9
Within-visit 112.8 17.2 53.9 2.6 91.6 21.9
Total 271.8 100.0 336.1 100.0 195.8 100.0
Abbreviations: PWV, pulse wave velocity; % total, percent of 
total variation; cfPWV, carotid-femoral PWV; baPWV, brachial-ankle 
PWV; faPWV, femoral-ankle PWV.
Table 4. Repeatability estimates and the minimal detectable 
change (MDC95) for PWV measures
PWV measure
ICC  
(95% CI)
SEM 
(cm/s)
MDC95 
(cm/s)
cfPWV 0.70 (0.59, 0.81) 148.3 411.0
baPWV 0.84 (0.78, 0.90) 133.7 370.6
faPWV 0.69 (0.59, 0.79) 108.7 301.4
Abbreviations: ICC, intraclass correlation coefficient, CIs, confi-
dence intervals; PWV, pulse wave velocity; MDC95, minimal detect-
able change; cfPWV, carotid-femoral PWV; baPWV, brachial-ankle 
PWV; faPWV, femoral-ankle PWV.
Figure  1. Minimal detectable difference (MDD) in PWV between 2 
independent samples, each of size N. Abbreviations: MDD, minimal 
detectable difference; PWV, pulse wave velocity; cfPWV, carotid-femoral 
PWV; baPWV, brachial-ankle PWV; faPWV, femoral-ankle PWV.
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the ICC of repeat measures of PWV on the same day was 
0.76 for cfPWV, 0.97 for baPWV, and 0.96 for faPWV within 
technicians. Between technicians, the ICC was 0.73 for 
cfPWV, 0.91 for baPWV, and 0.87 for faPWV.6 This analysis, 
however, was limited to repeat measurements taken on the 
same day at a single site.
Although the repeatability of PWV is similar across 
devices, slight variations exist due to the differences in how 
sensors capture arterial waveforms, the algorithm used to 
calculate PWV, and the path length measurements. The 
Omron VP-1000 Plus and Complior simultaneously meas-
ure waveforms oscillometrically with circular pulse wave 
sensors placed on the skin that may allow for a more repro-
ducible determination of the arterial wave signals than with 
handheld applanation tonometers used in other PWV meth-
ods, such as the SphygmoCor.
In our study baPWV had the highest repeatability, which 
is partly accounted for by the greater measurement disper-
sion and between-subject variability since more heteroge-
neous measures inherently give higher ICC estimates due 
to the nature of the calculation.21 The between-participant, 
between-visit, and within-visit variation we observed in 
PWV measures could be attributed to biological variation in 
hemodynamics and arterial anatomy, technician error, tech-
nical factors, sensor placement, and environmental factors. 
Differences in path length measurement would have con-
tributed to the between-visit variation in cfPWV. Variability 
in PWV could also differ by populations with various CVD 
risk factors and by age.17 Options to increase the reproduc-
ibility of PWV measures include averaging measures, stand-
ardizing procedures, and assembling larger sample sizes. 
Replicate measures are recommended,22 and the average of 
2 cfPWV measurements was shown to be comparable to the 
average of 3.17
The estimates of the MDC95 and MDD for PWV measures 
we report can aid in estimating study sizes and in evaluating 
whether PWV differences within participants or between-
participant groups are above measurement variation. For 
example, the MDC95 for cfPWV was 411 cm/s, suggesting 
that a change of more than 411 cm/s may be necessary in 
order to determine whether a change in cfPWV exceeds 
measurement variability. A  411 cm/s change in cfPWV 
may be clinically relevant as a cut point of 1,200 cm/s1,23 for 
cfPWV (using the straight distance from carotid to femoral 
artery) have been recommended for the risk of CVD.
Current recommendations focus on cfPWV as the estab-
lished measure of central arterial stiffness.2,24 In contrast, 
baPWV is widely used in East Asian countries, particularly 
in Japan, presumably due to the greater ease of measurement 
given that a carotid and femoral sensor are not required.25 
Although baPWV is a composite measure of central and 
peripheral arterial stiffness representing heterogeneous arte-
rial territories, it is proposed to have utility in CVD risk 
stratification.26–28
Our goal was to estimate short-term (4–8 week) repeat-
ability, for which we measured PWV at 2 time points. Most 
studies, in contrast, evaluated repeatability during a single 
visit. A  limitation of our study is that it was not designed 
to estimate variability due to technicians. As such, it is not 
a comprehensive evaluation of the main sources of meas-
urement variability, but incorporates variability due to 
technician(s) into process variability. In that sense our study 
mimics typical clinical practice and research settings where 
there are multiple technicians, or the technicians work in 
pairs. As a further limitation of our study, although all exam-
inations were conducted in the morning, using a standard-
ized protocol and study procedures designed to minimize 
measurement variability, it is possible that conditions were 
not identical. As above, this type of variability is included in 
our estimates as part of process variability. Lastly, it is impor-
tant to note that the calculations for the SEM and MDC 
assume that the measurement error and detectable change is 
constant across the range of values.
PWV is a widely used measure of arterial stiffness and 
has implications for clinical research and risk stratification. 
Repeatability was acceptable for all PWV measures in a mul-
ticenter, population-based study of older adults and sup-
ports its use in epidemiologic studies. Further investigation 
is needed to discern whether changes in cfPWV, baPWV, and 
faPWV are clinically meaningful. Toward this aim, we offer 
estimates to aid in designing and interpreting such studies. 
An understanding of PWV measurement variability is criti-
cal for applications to risk assessment and stratification and 
for translation to clinical practice.
SUPPLEMENTARY MATERIAL
Supplementary materials are available at American Journal 
of Hypertension (http://ajh.oxfordjournals.org).
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